Ad hoc:MorphoSys AG:Ad hoc: MorphoSys and Xencor Sign License and Collaboration Agreement for Clinical Antibody Program

Sunday, 27. June 2010 21:13
MorphoSys AG / / Ad hoc: MorphoSys and Xencor Sign License and Collaboration Agreement for Clinical Antibody Program processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.

MorphoSys Strengthens Clinical Portfolio with Innovative Antibody in Phase 1
Cancer Trial

MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) and US-based
biopharmaceutical company Xencor, Inc., announced today the signing of a
worldwide exclusive license and collaboration agreement for an antibody in Phase
1 clinical development. The agreement provides MorphoSys with an exclusive
worldwide license to XmAb5574, a high potency monoclonal antibody developed by
Xencor for the treatment of B-cell malignancies. As part of the agreement, the
companies will collaborate on the Phase 1 trial in patients with chronic
lymphocytic leukemia (CLL) in the U.S.A., for which Xencor will continue to
carry the costs under its development plan. MorphoSys will be solely responsible
for further clinical development. Xencor will receive an upfront payment of US$
13 million (approx. € 10.5 million), and will be eligible to receive
development-, regulatory- and commercialization-related milestone payments and
tiered royalties based on product sales. Further financial terms were not
disclosed.


With Xencor carrying the cost for the phase 1 trial of XmAb5574/MOR208,
MorphoSys continues to anticipate total internal investment in proprietary R&D
of € 26 - 29 million, as per the Company´s original guidance in February 2010.

END OF AD HOC RELEASE.


About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies
for therapeutic, diagnostic and research applications. The Company's HuCAL
technology is one of the most powerful methods available for generating fully
human antibodies. By successfully applying this and other proprietary
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human health-care.
Through its alliances with some of the world's leading pharmaceutical companies,
MorphoSys has created a pipeline of more than 60 drug candidates. The Company is
expanding its drug pipeline by adding new partnered programs, and by building a
portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio,
the Company is focused on the areas of oncology and inflammation. Its most
advanced program MOR103, a first-in-class, fully human antibody against GM-CSF,
is currently tested in a Phase Ib/IIa trial in rheumatoid arthritis patients.
Via its business unit AbD Serotec, MorphoSys is expanding the reach of its
technologies in the diagnostics and research markets. MorphoSys is headquartered
in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol
"MOR". For further information, visithttp://www.morphosys.com/


This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.


For more information, please contact:
MorphoSys AG

Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

investors@morphosys.com





[HUG#1427619]



--- End of Message ---

MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany

WKN: 663200;ISIN: DE0006632003;Index:TecDAX,Prime All Share,CDAX,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;


Ad hoc Release: http://hugin.info/130295/R/1427619/375290.pdf



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
All reproduction for further distribution is prohibited.

Source: MorphoSys AG via Thomson Reuters ONE
Related Links: MorphoSys AG
Author:
Hugin
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.